Pharma giant, GlaxoSmithkline Consumer Healthcare Ltd has declared that it has bagged final nod from USFDA for Naratriptan Hydrochloride tabs.

The company got nod to sell the tablets in the potencies of 2.5mg base and 1mg base.

Naratriptan hydrochloride pills are prescribed by the physician to put control over migraine attacks in grownups with or without aura.

GlaxoSmithKline Consumer Healthcare recorded an increase of 30.01% in its net profit at Rs 717.5 million for the quarter ended Jun. 30.

Net sales during the three month period surged 14.64% toRs 5,373.5 million.

At 12.43 p. m., the company's shares surged 0.33% to trade at Rs 1,812.00 on the BSE.

The overall volume of shares traded at BSE stood at 1,549.